Key result
Astaxanthin attenuates atherosclerosis in vitro by suppressing foam cell formation, oxidative stress, and inflammation.
Why the study?
Does astaxanthin inhibit foam cell formation and inflammation in atherosclerosis models?
Does astaxanthin inhibit foam cell formation and inflammation in atherosclerosis models?
Answers are grounded in this paper and cite their sources.
Astaxanthin demonstrates potential as a multitarget natural agent against atherosclerosis by targeting key proteins and inhibiting foam cell formation and inflammation in vitro.
Atherosclerosis (AS) is a major and common pathological basis of ischemic intestinal infarction, myocardial infarction, stroke, renal failure, and other highly lethal and disabling diseases. Current pharmacological interventions (e.g., statins) often cause adverse effects, limiting their long-term use. Natural compounds, with their multitarget efficacy and superior safety profiles, have emerged as promising alternatives for AS treatment. As a potent antioxidant carotenoid, astaxanthin exhibits unique therapeutic potential by simultaneously targeting inflammation, oxidative stress, and lipid metabolism, which are key drivers of AS pathogenesis. This study will systematically decipher astaxanthin’s therapeutic mechanisms through an integrative strategy encompassing artificial intelligence virtual screening and experimental validation. Notably, five proteins, including CTSD, DPP4, FABP5, ITGAL, and MMP9, were identified as core targets for astaxanthin intervention in AS via network pharmacology and machine learning. Meanwhile, the results from molecular dynamic simulations confirmed that these core targets can stable binding with astaxanthin. Furthermore, in vitro experiments further validated astaxanthin can inhibit foam cell formation, restore redox balance, and suppress inflammation. Moreover, a close correlation has been found between them. These findings position astaxanthin as a multitarget natural agent to combat AS, addressing both efficacy advantage and safety concerns of current therapies.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) studied Atherosclerosis. Astaxanthin was evaluated on Core targets for astaxanthin intervention and in vitro validation of foam cell formation, redox balance, and inflammation. Astaxanthin targets CTSD, DPP4, FABP5, ITGAL, and MMP9 in atherosclerosis, and in vitro experiments validated its ability to inhibit foam cell formation, restore redox balance, and suppress inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: